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DObjectives: The surgical approach for ischemic mitral regurgitation remains unclear. Many studies are in favor
of adding the subvalvular procedure to mitral annuloplasty to reduce recurrent mitral regurgitation. This study
reports the clinical and echocardiographic outcomes of papillary muscle relocation combined with mitral
annuloplasty.
Methods: From 2003, 115 patients with severe ischemic mitral regurgitation who underwent papillary muscle
relocation plus nonrestrictive mitral annuloplasty and coronary artery bypass grafting were retrospective
analyzed. Patients’ mean age was 52  12.8 years, New York Heart Association class III or IV was 71%,
and preoperative left ventricular ejection fraction was 43%  6%. The study end points were New York Heart
Association functional class, reversal in left ventricle remodeling, reduction of mean tenting area and mean
coaptation depth, freedom from cardiac-related deaths and events, and freedom from recurrent mitral
regurgitation. Follow-up data were obtained in all patients and were 100% complete. Mean follow-up was
45  6 months.
Results: Five-year freedom from cardiac-related death and events was 91.3%  1.6% and 84%  2.2%,
respectively. Recurrent mitral regurgitation more than moderate occurred in 3 patients (2.7%). Reversal in
left ventricular remodeling, measured by a change in the end-diastolic and systolic diameter, was observed in
our patients (P<.05). The postoperative mean tenting area and mean coaptation depth were 1.1  0.2 cm2
and 0.5  0.2 cm, respectively; 95% of the patients were in New York Heart Association functional class I
and II.
Conclusions: In patients with ischemic mitral regurgitation, papillary muscle relocation plus nonrestrictive
mitral annuloplasty promotes a significant reversal in left ventricular remodeling, with a considerable decrease
in tenting area and coaptation depth. Our approach is a durable method to reduce the recurrence of mitral
insufficiency. (J Thorac Cardiovasc Surg 2014;148:1947-50)In the era of mitral valve reconstruction, the surgical
approach for ischemic mitral regurgitation (IMR) remains
an open issue.1,2 Many surgeons prefer restrictive mitral
valve annuloplasty (R-MA), whereas others prefer mitral
valve replacement with subvalvular apparatus preservation
to avoid postoperative mitral regurgitation (MR).3-8 The
incidence of recurrent MR after isolated R-MAwas 5% to
20% in several reports.9,10 On the other hand, many
authors have advocated postinfarction ventricular
remodeling as the key issue in the development of
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The Journal of Thoracic and Carprocedure to annuloplasty to reduce the risk of
recurrent mitral valve insufficiency.11-13 This study
reports the midterm results of the clinical and
echocardiographic outcomes of papillary muscle (PPM)
relocation in conjunction with nonrestrictive mitral
annuloplasty (NR-MA) in IMR.MATERIALS AND METHODS
Patients
FromMarch 2003, 115 patients (mean age, 52  12.8 years; 56% were
male) with severe IMR (effective regurgitant orifice area 20 mm2,
regurgitant volume 30 mL) who had PPM relocation in conjunction
with NR-MA and coronary artery bypass grafting (CABG) were retrospec-
tively analyzed. New York Heart Association (NYHA) class greater than II
was present in 81 patients (71%), and mean left ventricular ejection
fraction (LVEF) was 43%  6%. According to Carpentier’s functional
classification,14 all patients with IMR presented restrictive systolic leaflets
motion (Carpentier’s type III b) and annular dilatation (Carpentier’s type I).
Mean coaptation depth and mean tenting area were 1.3  0.1 cm and
3.2  0.9 cm2, respectively. MR was defined as ischemic when caused
by coronary artery disease in patients who had a previous myocardial
infarction 2 weeks or more before hospital admission for CABG and
exhibited normal valve apparatus anatomy. Exclusion criteria were recent
myocardial infarction (<15 days), PPM infarction causing its elongation or
rupture, organic mitral valve lesions (rheumatic, infective, degenerative),diovascular Surgery c Volume 148, Number 5 1947
TABLE 1. Baseline and intraoperative data
Baseline
Mean age (y) 52  12.8
Male gender 65 (56%)
Diabetes mellitus 38 (33%)
COPD 12 (10.4%)
Hypertension 70 (60%)
Renal failure* 9 (7.8%)
Unstable angina 35 (30.4%)
CHF 44 (38%)
Atrial fibrillation 6 (5.2%)
NYHA>II 81 (71%)
euroSCORE 8.8  2.6
LVEF 43  6
LVEDD 58.8  12
LVESD 48.1  9
Mean tenting area 3.2  0.9
Mean coaptation depth 1.3  0.1
Intraoperative
CPB time (min) 114  20
Crossclamp time (min) 85  10
Grafts/patient 2.8  0.5
Values are mean standard deviation or number (%). CHF, Congestive heart failure;
COPD, chronic obstructive pulmonary disease; CPB, cardiopulmonary bypass;
euroSCORE, European System for Cardiac Operative Risk Evaluation; LVEDD,
left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction;
LVESD, left ventricular end-systolic diameter; NYHA, New York Heart Association.
*Serum creatinine greater than 1.5 mg/dL.
Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
CI ¼ confidence interval
HR ¼ hazard ratio
IMR ¼ ischemic mitral regurgitation
LV ¼ left ventricular
LVEF ¼ left ventricular ejection fraction
MR ¼ mitral regurgitation
NR-MA ¼ nonrestrictive mitral annuloplasty
NYHA ¼ New York Heart Association
PPM ¼ papillary muscle
R-MA ¼ restrictive mitral valve annuloplasty
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Dprevious cardiac surgery, and concomitant aortic valve surgery. Baseline
patient characteristics are shown in Table 1.
End Points
The study end points were as follows: incidence of early mortality and
outcomes, freedom from cardiac-related deaths and events, freedom from
recurrent MR 2 or greater, NYHA functional class, reverse in left
ventricular (LV) remodeling, evaluationof tenting area, and coaptationdepth.
A cardiac event was defined as the occurrence of at least 1 of the following:
myocardial infarction, congestive heart failure, cardiac death, revasculariza-
tion (CABG or percutaneous intervention), new onset of atrial fibrillation,
redo operation on the mitral valve, worsening in NYHA functional class,
recurrent MR grade of 2 or greater, and hospital readmission.
Surgical Technique
All patients underwent conventional multivessel CABG via a longitudi-
nal median sternotomy under normothermic cardiopulmonary bypass with
intermittent antegrade cold-blood cardioplegia. The bypass grafts used
were the internal thoracic artery and the long saphenous vein in all patients.
All distal anastomoses were performed during a single aortic crossclamp-
ing. The proximal graft anastomoses were performed during side-clamping
(Table 1).
Mitral valve annuloplasty was performed using the Carpentier-Edwards
Physio ring (Edwards Lifesciences, Irving, Calif) or the Saddle Rigid ring
(St Jude Medical, Minneapolis, Minn). The ring size was determined
according to the surface of the anterior leaflet. In regard to our non-
restrictive annuloplasty, we used the normal-sized ring, not the undersized.
In patients who undergo PPM relocation, the use of a ring according to the
anterior leaflet surface may be effective without having to risk an
undersizing. Rings were inserted using deep horizontal U sutures and
Ticron 2-0 stitches (Syneture, Norwalk, Conn).
Relocation of the PPMs was performed using a polytetrafluoroethylene
suture (CV-4 Gore-Tex; WLGore & Associates Inc, Flagstaff, Ariz) placed
first at the head of each PPM and subsequently through the ipsilateral mitral
annulus while the heart was arrested, according to the technique described
by Kron and colleagues.12 We relocate both PPMs to minimize the mitral
valve tenting. In most cases, 1 head of the anterior PPM was relocated. On
the other hand, among the 3 heads of the posterior PPM, we relocated the
anterior and posterior heads. It is important to relocate both heads of the
posterior PPM because from the anterior, one head arises from the chordae
for the anterior leaflet responsible for the seagull sign and respective
tenting, and from the posterior, one head arises from the chordae to the
posterior leaflet (P2 and P3 scallops).15
All patients underwent postoperative transesophageal assessment of the
LV and valve function. Mitral valve repair was considered successful if1948 The Journal of Thoracic and Cardiovascular Surthere was no or trivial residual MR and a coaptation surface of
approximately 0.8 cm.
Follow-up
All patients were followed by our cardiologists at 6-month intervals.
Preoperative and postoperative clinical status were determined according
to the criteria of the NYHA functional class and the Canadian
Cardiovascular Society for heart failure symptoms and angina,
respectively. Clinical follow-up data were obtained in all patients and
were 100% complete. Mean follow-up was 45  6 months.
Statistical Analysis
The numeric values are expressed as mean  standard deviation.
The frequency ratios are given as percentages. LV end-diastolic and
end-systolic diameters, and LVEF percentage were analyzed using the
paired t test and Wilcoxon signed-rank test. Variables were put into a
Cox regression model. Where appropriate, hazard ratios (HRs) are
presented with 95% confidence intervals (CIs). Actuarial survival and
other time-related events were analyzed with the Kaplan–Meier method.
Log-rank test was used to compare statistical significance level. SPSS
software (SPSS Inc, Chicago, Ill) was used.RESULTS
Early Outcomes
Of the entire population, 4 patients (3.4%) died
in-hospital. Causes of in-hospital death were low cardiac
output in 2 patients, sepsis in 1 patient, and multiorgan
failure in 1 patient. Intra-aortic balloon pump implantation
was required to treat postoperative cardiogenic shock in
2 patients (1.7%). Renal failure requiring dialysis was
present in 4 patients (3.4%). All data are shown in Table 2.gery c November 2014
TABLE 2. Early outcomes and follow-up data
Early outcomes
Bleeding with resternotomy 6 (5.2%)
Renal failure (dialysis) 4 (3.4%)
ETI>72 h 7 (6%)
LCOS 2 (1.7%)
Sepsis 1 (0.8%)
MOF 1 (0.8%)
IABP 2 (1.7%)
ICU stay (d) 2.1  1.8
In-hospital mortality 4 (3.4%)
Follow-up data
Late mortality 5 (4.5%)
NYHA class>II 4 (3.6%)
Hospital readmission for CHF 4 (3.6%)
Recurrent MR II 3 (2.7%)
Mean tenting area (cm2) 1.1  0.2
Mean coaptation depth (cm) 0.5  0.2
LVEDD (mm) 49  5
LVESD (mm) 39  4
Mean LVEF% 49  3
Values are presented as mean  standard deviation or number (%). CHF, Congestive
heart failure; ETI, endotracheal intubation; IABP, intra-aortic balloon pump;
ICU, intensive care unit; LCOS, low cardiac output syndrome; LVEDD, left
ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction;
LVESD, left ventricular end-systolic diameter; MOF, multiorgan failure; MR, mitral
regurgitation; NYHA, New York Heart Association.
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Kaplan–Meier estimate for cumulative survival at 5 years
was 91%  1.3% after PPM relocation plus NR-MA.
Five-year freedom from cardiac-related death rate was
91.3%  1.6% (Figure 1, A). Late cardiac deaths occurred
in 5 patients (4.5%). Causes of late death were congestive
heart failure in 2 patients, arrhythmias in 2 patients, and
sudden death in 1 patient. The following independent
variables for late mortality in the entire population were
found by Cox analysis: LVEF 30% or less (P ¼ .003;
HR, 8; 95% CI, 2.2-37) and NYHA class III or greater
(P ¼ .006; HR, 5.5; 95% CI, 1.5-44). Five-year freedomFIGURE 1. Kaplan–Meier log-rank test used to compare cardiac-related deat
MR, Mitral regurgitation.
The Journal of Thoracic and Carfrom cardiac-related events was 84%  2.2%
(Figure 1, B). Five-year freedom from recurrent MR
grade of 2 or greater was 97.3%  1.1% (Figure 1, C).
At follow-up, NYHA functional class improved from
3.1  1.1 to 1.3  0.3 (P ¼ .018).Echocardiographic Data
Recurrent moderate or more than moderate MR occurred
in 3 patients (2.7%). Significant reversal in LV remodeling
measured by a change in LV end-diastolic and end-systolic
diameters was observed in our patients (P<.05). The LVEF
improved from 43  6 to 49  3 (P<.05). Postoperative
mean tenting area was 1.1  0.2 cm2, and postoperative
mean coaptation depth was 0.5  0.2 cm, with significant
reduction in respect to preoperative data (P < .001)
(Table 3).CONCLUSIONS
Although the surgical treatment of severe IMR in patients
presenting for CABG is recommended by the American
College of Cardiology/American Heart Association and
European Society of Cardiology/European Association for
Cardiothoracic Surgery guidelines,1,2 the best surgical
approach is still under debate. Several clinical studies
provide only limited information about the dilemma to
repair or replace the mitral valve in patients with severe
IMR.5,7 This conflicting decision is mainly affected by the
lack of prospective studies and often by the comparison of
clinical outcomes for both procedures in dissimilar patient
groups.
Currently, R-MA is still associated with poor outcomes in
many series16,17 for many reasons. First, there is a wide
heterogeneity in the literature in the type of prosthetic
ring (eg, complete, band, rigid, flexible, pericardium) used
to achieve mitral annuloplasty, which inexorably leads to
dissimilar results. Second, R-MA was performed in all
patients with IMR despite the degree of LV dilatation andhs (A), cardiac-related events (B), and recurrent MR grade of 2 or greater.
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TABLE 3. Comparison of echocardiographic data from preoperative
to follow-up
Variable Preoperative Follow-up P value
Mean tenting area (cm2) 3.2  0.9 1.1  0.2 <.001
Mean coaptation depth (cm) 1.3  0.1 0.5  0.2 <.001
LVEDD (mm) 58.8  12 49  5 <.05
LVESD (mm) 48.1  9 39  4 <.05
Mean LVEF% 43  6 49  3 <.05
Values are mean  standard deviation or number (%). LVEDD, Left ventricular end-
diastolic diameter; LVEF, left ventricular ejection fraction; LVESD, left ventricular
end-systolic diameter.
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D dysfunction and the severity of mitral valve tenting
associated with PPM displacement. Thus, surgeons
routinely perform R-MA as a unique surgical solution for
a complex LV disease. Several authors have proposed
different surgical techniques (eg, PPM relocation, second
chordae cutting, PPM sling)11-13 in addition to R-MA to
improve long-term repair results. In this series, we present
our experience on PPM relocation. This technique was first
introduced by Kron and colleagues12 and may be easy and
reproducible.
LV reverse remodeling has been observed after R-MA.4,8
However, it is not clear whether PPM relocation has a
favorable effect on LV reverse remodeling for isolated
R-MA. Our group recently published 2 articles that
compare the results of PPM relocation and NR-MA with
isolated R-MA.15,18 We demonstrated that PPM relocation
reduces the tenting area and coaptation depth, leading to a
low incidence of recurrent MR and promoting a better
reverse in LV remodeling compared with isolated R-MA.
PPM relocation is a safe method, with low early and late
mortality. This technique reduces the tenting area and
coaptation depth, leading to a low incidence of recurrent
MR and probably avoiding further displacement of the
PPMs. Moreover, PPM relocation promotes a better reverse
in LV remodeling.References
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